Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)
05 3월 2025 - 8:00PM
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and
globally integrated biopharmaceutical company is pleased to
announce it has entered into an exclusive distribution agreement
for the territories of Australia and New Zealand. Immuron will
launch ProIBS® for the treatment of symptoms related to IBS in the
retail pharmacy sales channel. Immuron has been a leader in
digestive health in Australia for many years. ProIBS® will join
Immuron’s product portfolio which includes the rapidly growing
Travelan® brand building on the premium efficacy product range that
will deliver better outcomes for consumers that Pharmacists will
love to recommend.
Irritable bowel syndrome (IBS) is a common
condition where you experience symptoms related to your digestive
system. This is sometimes linked to certain foods, lifestyle habits
and stress levels or mood. IBS affects around 3 out of every 10
people. Females are more likely than males to be affected. Some key
symptoms of IBS include: abdominal pain or discomfort; stomach
bloating and wind; chronic diarrhoea or constipation, or
alternating between the two.1 According to available data, the IBS
treatment market in Australia is estimated to be a part of the
broader "Digestives & Intestinal Remedies" market, generating a
revenue of around AU$221.14 million in 2025, with a projected
annual growth rate of 3.28%.2
ProIBS® is a certified medical device for the
treatment of IBS symptoms such as abdominal pain, bloating and
unsettled bowel movements (diarrhoea and/or constipation). ProIBS®
contains AVH200®, derived from the plant Aloe barbadensis Miller.
AVH200® has gel forming components which support the intestinal
mucosal barrier. As IBS is known to affect individuals for a long
period of time, it is essential to have a treatment appropriate for
long-term use – as ProIBS® is. The product is safe, and no
interactions with other medications are known. Science-driven
innovative Calmino group AB, the developer of ProIBS®, conducted a
usability study among 1,003 users. ProIBS® was helpful for 94% of
them. 91% of the users experienced an improvement in daily life and
98% would recommend ProIBS® to someone else. To learn more please
check: www.proibs.eu.
Flavio Palumbo, Chief Commercial Officer said,
“Following the rapid growth of Travelan in pharmacy as the leading
product for the prevention of traveller’s diarrhoea3, we have
identified a great opportunity with ProIBS® to further expand our
digestive health portfolio by providing pharmacists a proven
premium efficacy product that delivers unique benefits to their
customers. With ProIBS®, we are able to provide an innovative and
European certified medical device for the treatment of symptoms
related to IBS. The product has been on the Swedish pharmacy market
for more than a decade. Because it is backed by science and
recommended by physicians and dietitians, we can promote ProIBS®
with absolute confidence. We are looking forward to offering a
solution that truly improves the liveability of the affected
people.”
Tobias Kisker, CEO and founder of Calmino group
AB, is pleased to start a long and successful collaboration with
Immuron. “The Calmino team is happy to work with a
well-established, experienced, and professional company like
Immuron. We see Australia and New Zealand as important Asian
Pacific markets with significant potential.”
-
https://www.healthdirect.gov.au/irritable-bowel-syndrome-ibs
-
https://www.statista.com/outlook/hmo/otc-pharmaceuticals/digestives-intestinal-remedies/australia
- Otto W, Najnigier B, Stelmasiak T, Robins-Browne RM. Randomized
control trials using a tablet formulation of hyperimmune bovine
colostrum to prevent diarrhoea caused by enterotoxigenic
Escherichia coli in volunteers. Scandinavian Journal of
Gastroenterology. 2011;46:862-868.
This release has been authorised by the directors of Immuron
Limited.
COMPANY
CONTACT:
Steven LydeamoreChief Executive OfficerPh: +61
(0)3 9824 5254info@immuron.com
About ImmuronImmuron Limited
(ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical
company focused on developing and commercializing orally delivered
targeted polyclonal antibodies for the treatment of inflammatory
mediated and infectious diseases.
For more information visit:
https://www.immuron.com.au
FORWARD-LOOKING STATEMENTS:
This press release may contain “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934,
each as amended. Such statements include, but are not limited to,
any statements relating to our growth strategy and product
development programs and any other statements that are not
historical facts. Forward-looking statements are based on
management’s current expectations and are subject to risks and
uncertainties that could negatively affect our business, operating
results, financial condition and stock value. Factors that could
cause actual results to differ materially from those currently
anticipated include: risks relating to our growth strategy; our
ability to obtain, perform under and maintain financing and
strategic agreements and relationships; risks relating to the
results of research and development activities; risks relating to
the timing of starting and completing clinical trials;
uncertainties relating to preclinical and clinical testing; our
dependence on third-party suppliers; our ability to attract,
integrate and retain key personnel; the early stage of products
under development; our need for substantial additional funds;
government regulation; patent and intellectual property matters;
competition; as well as other risks described in our SEC filings.
We expressly disclaim any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in our expectations or any
changes in events, conditions or circumstances on which any such
statement is based, except as required by law.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/e0632d8c-8807-41a6-ad8f-a65fa3b15f6a
Immuron (NASDAQ:IMRN)
과거 데이터 주식 차트
부터 2월(2) 2025 으로 3월(3) 2025
Immuron (NASDAQ:IMRN)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 3월(3) 2025